The CH50 is a screening assay for the activation of the classical complementpathway and it is sensitive to the reduction, absence and/or inactivity of any component of the pathway. SLE (systemic lupus erythematosus) patient's response to therapy; may predict disease flare in SLE; evaluate for complement component deficiency; evaluate complement activity in cases of immune complex disease, glomerulonephritis, rheumatoid arthritis, SBE, cryoglobulinemia. The CH50 assay mainly evaluates the classical pathway. Complement proteins can be increased as part of the acute-phase response to inflammation or infection, and they can be decreased or absent due to hypercatabolism, expenditure in immune complexes, or hereditary deficiency. Patients with hereditary absence of a complement protein may have decreased total complement and recurrent bacterial infections or a rheumatic illness. Conversely, patients with rheumatic diseases, particularly with active illness and activation of complement and formation of immune complexes, may have low total complement. Falling complement levels may presage clinical flares, particularly of lupus nephritis.
No special preparation is needed for CH50 Classical Pathway. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing CH50 Classical Pathway. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||41 - 90 hemolytic units|
|UNISEX||All age groups||16 - 33 mg/dl|
|MALE||All age groups||88 - 252 mg/dl|
|FEMALE||All age groups||88 - 206 mg/dl|
|MALE||All age groups||12 - 72mg/dl|
|FEMALE||All age groups||13 - 75mg/dl|